Abstract: A panel cutter has a clamping mechanism positioned adjacent to the cutting path to hold the panel material in position during the cutting process. The clamping mechanism includes a clamping bar which is removably coupled to a pair of lever mechanisms which are rotatably coupled to the framework of the panel cutter. An actuator bar having cams at both ends is also coupled to the framework and position adjacent to the lever arms, wherein movement of the actuator bar causes movement of the lever arms. Based upon the configuration and positioning of these components, movement of the lever arms causes the clamping bar to move between a locked position and an unlocked position.

Abstract: A panel cutter has a clamping mechanism positioned adjacent to the cutting path to hold the panel material in position during the cutting process. The clamping mechanism includes a clamping bar which is removably coupled to a pair of lever mechanisms which are rotatably coupled to the framework of the panel cutter. An actuator bar having cams at both ends is also coupled to the framework and position adjacent to the lever arms, wherein movement of the actuator bar causes movement of the lever arms. Based upon the configuration and positioning of these components, movement of the lever arms causes the clamping bar to move between a locked position and an unlocked position.

Abstract: The safe and efficient cutting of window blinds can be accomplished by utilizing a blind cutting system which is configured to support and contain the blinds in a desired position, and to have a cutting saw move along a cutting plane such that a cutting blade will interact with the blinds and cut a predetermined portion from an end thereof. A framework is used to support the cutting saw and allow movement of a cutting blade in a very controlled manner, thus avoiding any possibility that the blade is positioned in a dangerous position during operation. Further, the travel of the cutting blade along a cutting path will create a cutting action in a controlled and defined manner. Further, the cutting blade is shielded on virtually all sides, thus eliminating the possibility of injury or harm to a user.

Abstract: The present invention provides therapeutic compositions and methods for vector-mediated delivery and in vivo expression of polynucleotides encoding anti-cancer compounds that are effective in the treatment of cancer. In particular, the invention relates to the use of recombinant viral and non-viral vectors to deliver genes encoding one or more anti-angiogenic or proapoptotic gene products for the treatment of cancer.

Abstract: The present invention provides therapeutic compositions and methods for vector-mediated delivery and in vivo expression of polynucleotides encoding anti-cancer compounds that are effective in the treatment of cancer. In particular, the invention relates to the use of recombinant viral and non-viral vectors to deliver genes encoding one or more anti-angiogenic or proapoptotic gene products for the treatment of cancer.

Abstract: The present invention provides anti-angiogenic compositions and methods, based on gene delivery vectors that include the coding sequence for an anti-angiogenic compound.

Abstract: Suppressor tRNA's are used to regulate expression of transgenes that are toxic, or the expression thereof requires a factor that is toxic, to the host cell.

Abstract: Methods disclosed herein capitalize on the ability of DNA Structure Specific Recognition Proteins (SSRPs) to bind to genomic lesions formed by chemotherapeutic agents, particularly cisplatin-type agents. Methods are provided for predicting whether an agent that damages DNA will also be cytotoxic, and for predicting whether particular eukaryotic cells will be susceptible to killing by a genotoxic drug. A screening method is provided for identifying new genotoxic drugs that produce SSRP-recognized lesions in DNA. Methods also are provided for sensitizing particular eukaryotic cells to killing by chemotherapeutic agents, particularly cisplatin-type drugs.

Abstract: Suppressor tRNA's are used to regulate expression of transgenes that are toxic, or the expression thereof requires a factor that is toxic, to the host cell.

Abstract: Methods disclosed herein capitalize on the ability of DNA Structure Specific Recognition Proteins (SSRPs) to bind to genomic lesions formed by chemotherapeutic agents, particularly cisplatin-type agents. Methods are provided for predicting whether an agent that damages DNA will also be cytotoxic, and for predicting whether particular eukaryotic cells will be susceptible to killing by a genotoxic drug. A screening method is provided for identifying new genotoxic drugs that produce SSRP-recognized lesions in DNA. Methods also are provided for sensitizing particular eukaryotic cells to killing by chemotherapeutic agents, particularly cisplatin-type drugs.

Abstract: DNA structure specific recognition protein of eukaryotic origin and DNA encoding such a factor, as well as probes specific for DNA structure specific recognition protein or DNA encoding it and methods of detecting DNA structure specific recognition protein in eukaryotic cells. In particular, a mammalian cellular factor that selectively recognizes and binds DNA damaged or modified by a drug (the anticancer drug, cis-diamminedichloroplatinum (II) or cisplatin) has been identified.

Abstract: DNA structure specific recognition protein of eukaryotic origin and DNA encoding such a factor, as well as probes specific for DNA structure specific recognition protein or DNA encoding it and methods of detecting DNA structure specific recognition protein in eukaryotic cells. In particular, a mammalian cellular factor that selectively recognizes and binds DNA damaged or modified by a drug (the anticancer drug, cis-diamminedichloroplatinum (II) or cisplatin) has been identified.